as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹124.87
Change
+1.72 (1.4%)
Open
₹123.15
Prev. Close
₹123.15
Day High
₹126.5
Day Low
₹119.52
Volume Analysis
Traded
62,693
Delivered
178,511
Delivery %
49.05%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (-1.2%)
- •Below-average fundamentals quality score (43/100)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹134.72 | ₹130.61 | ₹127.74 | ₹123.63 | ₹120.76 | ₹116.65 | ₹113.78 |
| Fibonacci | ₹130.61 | ₹127.94 | ₹126.3 | ₹123.63 | ₹120.96 | ₹119.32 | ₹116.65 |
| Camarilla | ₹126.79 | ₹126.15 | ₹125.51 | ₹123.63 | ₹124.23 | ₹123.59 | ₹122.95 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+81.55%
1 Week
-1.74%
1 Month
+25.31%
3 Months
+92.11%
6 Months
+119.3%
1 Year
+51.28%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
3.97%
Net margin 5.23% × asset turnover 0.51x × equity multiplier 1.49x
Company Overview
Sector
Healthcare
Market Cap
₹678 Cr
P/E (TTM)
42.4
ROE
-1.2%
Book Value
₹57.2
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Valiant Laboratories Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-1.2%); below-average fundamentals quality score (43/100). FII holding has been falling.
TopFund Score — Fundamentals Quality
43/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is expected to give good quarter
- −Company has a low return on equity of -1.41% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board approved up to ₹70 lakh investment in AMPYR Renewable Energy for solar power at Tarapur plant.
Newspaper Advertisement regarding Completion of Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the Members of the Company
Ind-Ra assigned IND BBB/Stable and IND A2 ratings to INR 560 million bank loan facilities.
Valiant Labs dispatched FY2025-26 annual report and AGM notice; AGM on September 28, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 51 | 60 | 41 | 31 | 19 | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses + | 48 | 61 | 47 | 35 | 21 | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating Profit | 4 | -1 | -6 | -5 | -2 | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | 7.0% | -2.3% | -16.0% | -15.0% | -13.0% | -31.0% | 1.8% | 7.0% | 5.0% | 0.2% | -1.7% | 5.0% | 25.0% |
| Other Income + | 2 | 3 | 2 | 2 | 3 | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | 6 | 1 | -5 | -3 | 0 | -4 | 2 | 1 | 2 | 0 | -3 | 1 | 26 |
| Tax % | 26.0% | 25.0% | -31.0% | -52.0% | 219.0% | 21.0% | -44.0% | 26.0% | 26.0% | 25.0% | 136.0% | -68.0% | 19.0% |
| Net Profit + | 4 | 1 | -4 | -1 | -1 | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS in Rs | 1 | 0 | -1 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 | 4 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 334 | 182 | 133 | 237 | 306 |
| Expenses + | 299 | 190 | 138 | 231 | 273 |
| Operating Profit | 35 | -8 | -5 | 6 | 33 |
| OPM % | 11.0% | -4.6% | -3.5% | 2.7% | 11.0% |
| Other Income + | 5 | 10 | 5 | 2 | 3 |
| Interest | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 6 | 8 |
| Profit before tax | 38 | -1 | -2 | 1 | 25 |
| Tax % | 24.0% | -142.0% | 46.0% | 525.0% | — |
| Net Profit + | 29 | 0 | -2 | -3 | 16 |
| EPS in Rs | 7 | 0 | 0 | -1 | 3 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Reserves | 68 | 193 | 191 | 257 |
| Borrowings + | 60 | 77 | 122 | 46 |
| Other Liabilities + | 52 | 29 | 45 | 107 |
| Total Liabilities | 213 | 343 | 401 | 464 |
| Fixed Assets + | 48 | 50 | 48 | 227 |
| CWIP | 1 | 43 | 156 | 6 |
| Investments | 34 | 38 | 0 | 28 |
| Other Assets + | 130 | 212 | 197 | 202 |
| Total Assets | 213 | 343 | 401 | 464 |
| Equity Capital | 33 | 43 | 43 | 54 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 56 | 2 | 1 | -10 |
| Cash from Investing Activity + | -55 | -144 | -53 | 7 |
| Cash from Financing Activity + | -1 | 152 | 45 | 2 |
| Net Cash Flow | 0 | 10 | -7 | -1 |
| CFO/OP | 185 | -11 | 25 | -147 |
| Free Cash Flow | 18 | -44 | -112 | -45 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 14.66% | 17.54% | 21.58% | 23.18% | 25.06% | 25.06% | 24.42% | 23.97% | 25.05% | 25.05% | 24.87% | 25.06% |
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FII | 8.64% | 7.08% | 3.48% | 1.89% | 0.0% | 0.0% | 0.64% | 0.63% | 0.02% | 0.01% | 0.2% | 0.0% |
| DII | 1.76% | 0.43% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.46% | 0.0% | 0.0% | 0.0% | 0.0% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Valiant Laboratories Ltd (this stock) | 678 | 42.4 | 2.19 | -1.2% |
| Fabtech Technologies Ltd | 661 | 13.6 | 1.58 | 12.5% |
| Zim Laboratories Limited | 716 | 194.0 | 2.42 | 1.59% |
| Wanbury Limited | 784 | 18.2 | 12.38 | 76.5% |
| Kilitch Drugs India Ltd | 786 | 26.2 | 2.81 | 10.6% |
| Gaudium Ivf N Women H L | 837 | 36.2 | 5.55 | 24.7% |
| Bafna Pharmaceuticals Ltd | 842 | — | 1.65 | -6.18% |
Which Mutual Funds Hold Valiant Laboratories Ltd?
Frequently Asked Questions about Valiant Laboratories Ltd
Valiant Laboratories Ltd (VALIANTLAB) closed at ₹124.87 on NSE on 25 September 2026, up 1.72 (1.4%) from the previous close.
Valiant Laboratories Ltd trades on the NSE (National Stock Exchange of India) under the symbol VALIANTLAB.
Valiant Laboratories Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 42.4.
Valiant Laboratories Ltd has a dividend yield of 0.0%.
Valiant Laboratories Ltd's 52-week high is ₹132.0 and its 52-week low is ₹49.5.
Valiant Laboratories Ltd has a market capitalisation of ₹678 crore.
Valiant Laboratories Ltd has a TopFund Quality Score of 43/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Valiant Laboratories Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.